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Abstract. Cerebrospinal fluid (CSF) is enriched in brain-derived components and represents an accessible and appealing
means of interrogating the CNS milieu to study neurodegenerative diseases and identify biomarkers to facilitate the devel-
opment of novel therapeutics. Many such CSF biomarkers have been proposed for Huntington’s disease (HD) but none has
been validated for clinical trial use. Across many studies proposing dozens of biomarker candidates, there is a notable lack of
statistical power, consistency, rigor and validation. Here we review proposed CSF biomarkers including neurotransmitters,
transglutaminase activity, kynurenine pathway metabolites, oxidative stress markers, inflammatory markers, neuroendocrine
markers, protein markers of neuronal death, proteomic approaches and mutant huntingtin protein itself. We reflect on the
need for large-scale, standardized CSF collections with detailed phenotypic data to validate and qualify much-needed CSF
biomarkers for clinical trial use in HD.
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INTRODUCTION
Despite over two decades of research since the
identification of the specific cause of Huntington’s
disease (HD), there remains no treatment that can pre-
vent the onset or slow down the progression of this
devastating autosomal dominant neurodegenerative
condition [1].
The cellular and molecular processes underlying
the natural history of the disease have been well char-
acterized since the causative gene mutation in HTT
was discovered in 1993 [2]. A CAG trinucleotide
repeat expansion leads to a mutant, polyglutamine-
expanded form of the HTT protein (mHTT) which
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aggregates and is toxic to neuronal cells, particularly
to vulnerable striatal cells. This gives rise to neuronal
dysfunction and death and ultimately the signs and
symptoms of HD [3].
However, several novel therapeutic candidates are
in ongoing or planned clinical trials, perhaps most
noteworthy being the various ‘gene silencing’ or
huntingtin-lowering approaches that use targeted
nucleotide-based therapeutics to reduce expression
of mHTT. The first clinical trial of such a therapy –
an antisense oligonucleotide therapeutic called Ionis-
HTTRx – is now underway [4].
Current clinical outcome measures such as the
unified Huntington’s disease rating scale (UHDRS)
[5] are well-established and will remain important
for the conduct of trials and licensing of novel
drugs. But they are limited by lack of ability to dis-
tinguish between symptom relief and amelioration
of the underlying pathological process, and are by
nature subjective and subject to inter- and intra-rater
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variability and the influence of confounders such as
the placebo effect [6]. In addition, by definition they
offer no ability to detect preclinical changes that
occur in HTT gene mutation carriers who are yet to
develop signs of symptoms of HD. With the ultimate
goal of treating individuals to prevent neurodegener-
ation and disease onset, this shortfall presents a huge
obstacle in the design of future trials of prospective
therapies.
The development of disease-specific biomarkers
has never been more important. In order for these
treatments to be validated it will be essential to have
objective and reliable measures.
A biomarker may serve one or more specific func-
tions: diagnostic, aiding more precise definition of
onset; prognostic, giving an indication of how the
disease will develop in an individual; natural his-
tory, to more accurately determine disease stage; and
finally pharmacokinetic, pharmacodynamic and
efﬁcacy biomarkers, that may independently assess
therapeutic response to and the effectiveness of a
potential intervention. Biomarkers need to be quan-
titative and ideally, quantification should be easy
and cheap; certainly, it should be reliable. Some
particularly robust biomarkers may, after an exten-
sive, formal process of evaluation and validation
[7, 8], be qualified for use as surrogate endpoints
for clinical trials leading to regulatory approval,
but many possible functions of biomarkers such as
elucidating pathobiology and informing go/no-go
decisions can be fulfilled with less stringent levels of
scrutiny.
Much progress has been made in recent years in
developing and evaluating biomarkers for HD, most
notably in the fields of quantitative clinical mea-
sures and cognitive measures where studies such as
TRACK-HD have, through head-to-head compari-
son of candidate biomarkers, effectively defined a
toolkit of robust biomarkers for use as outcome mea-
sures in clinical trials [9, 10]. Numerous trials now
in progress employ these biomarkers as secondary
or exploratory endpoints (regulatory approval on the
basis of a surrogate primary endpoint is a milestone
yet to be attained by any biomarker in neurodegener-
ative disease) [11–13].
Modifying the course of a progressive disease
requires an understanding of the chemistry and biol-
ogy of health, their derangement by the disease, and
their modulation by an intervention. This is difficult
to do without tools to interrogate directly the bio-
chemical milieu of the affected system – in the case
of HD, the human central nervous system. Direct
sampling of the target organ by brain biopsy is pos-
sible but carries high risk. Conventional imaging
methods can tell us about brain structure but are indi-
rect and cannot report on the biochemical changes
underlying structural pathology. Molecular imaging
techniques, such as magnetic resonance spectroscopy
or positron emission tomography, can only report on a
limited repertoire of chemical substances or changes.
Biofluid markers that reflect neuropathology, ideally
by virtue of being centrally involved in it, are there-
fore highly desirable – but so far notably lacking in
HD [3, 6, 14].
It is theoretically possible to identify and quantify
substances in more accessible biofluids, such as blood
and urine, that are derived from the CNS and altered
by the progression of a neurodegenerative disease,
and can be distinguished from peripherally-derived
substances. The quest for robust biofluid biomark-
ers in HD has hitherto yielded no such substances.
Changes have been reported that are detectable in
peripheral blood and that reflect matched peripheral
and central processes, including putative neuroin-
flammatory [15] and metabolic markers [16]. In most
cases the overwhelming mass of the peripheral tis-
sues inevitably dwarfs the contribution of substances
that are released from dying neurons and can pen-
etrate the blood-brain barrier, especially given the
very slow rate of CNS cell death in HD. Even seem-
ingly ‘CNS-specific’ entities that can be detected in
peripheral blood, such as brain-derived neurotrophic
factor (BDNF) [17], may have peripheral sources that
confound their interpretation [18].
Changes in peripheral biofluids that nonetheless
mirror neuropathology could have some function
as biomarkers of early efficacy, but only in the
very defined situation of a therapeutic confidently
expected to act in the same manner centrally and
peripherally; or as an indication of ‘overflow’ into
the peripheral circulation of a CNS-administered
drug. TR-FRET detection of mHTT in blood-derived
leukocytes might, for instance, be used to assess
target engagement by a peripherally-administered
huntingtin-lowering compound [19] that was known
to be brain-penetrant.
There remains a clear need for biochemical mark-
ers that can reliably inform us about neuropathology.
Cerebrospinal fluid (CSF), is produced within the
CNS and, while it begins as an ultrafiltrate of blood
plasma, it receives substantive contributions from the
brain. That 20% of its protein content is brain-derived
[20] gives reason to hope that relevant CSF biomark-
ers can be identified. Experience from other neu-
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rodegenerative diseases suggests that such markers
can be found and can be useful – e.g. -amyloid
and tau protein in Alzheimer’s disease (AD) [21] or
-synuclein and phosphorylated tau in Parkinson’s
disease (PD) [22] and that the lumbar puncture (LP)
or ‘spinal tap’ procedure by which CSF is routinely
obtained is safe and well-tolerated even for obser-
vational studies [23]. Despite our certainty of the
cause of the disease, the field of CSF biomarkers for
HD lags behind the more common neurodegenerative
diseases.
Studying CSF is not a novel idea in HD research.
Molecules have been quantified in HD CSF since the
early 1970s but progress has been hampered by low
sample numbers, inconsistent procedures, relatively
unreliable quantification techniques and a lack of tar-
gets investigated with a plausible mechanistic link to
HD pathology. Few if any results have been repli-
cated and we have no validated CSF biomarkers for
any aspect of HD.
Nonetheless there has been much recent progress.
Here we review previous CSF studies in HD and
consider what robust biomarker leads have been
identified. Figure 1 summarizes HD CSF biomarker
research over the past four decades. We conclude
with a focus on the most promising targets and work
underway to prosecute them efficiently.
NEUROTRANSMITTERS
The earliest studies examining CSF in HD took a
particular interest in neurotransmitters as a quantifi-
able surrogate for neuronal function and dysfunction.
GABAergic medium spiny neurons were known to
degenerate early in HD, triggering studies of CSF
GABA. The first study successfully to detect GABA
in HD CSF, in 1977, used a radioreceptor assay
[24]. Lower GABA levels were observed in 19 HD
patient CSF samples compared to a control group
of 26 subjects with other neurological and psychi-
atric disorders [25]. Manyam and colleagues included
individuals at-risk for developing HD in their inves-
tigation of CSF GABA in HD [26] (it would be
Fig. 1. A timeline of CSF biomarker studies in HD. Substances previously reported to change significantly in HD compared to controls are
marked by the year of first published finding. Triangular markers indicate the identification of the HTT gene as the cause of HD.
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5 further years before a genetic marker was found
and 15 before the HTT gene was identified). A sub-
set of the at-risk individuals had lower than normal
CSF GABA closer to the patients with HD, suggest-
ing there could be early changes in GABA before
symptoms manifest. Homocarnosine, a dipeptide
containing GABA, was later found to be significantly
lower in HD patient CSF [27]. In contrast Bonnet et al.
found total GABA and homocarnosine to be signif-
icantly higher in HD CSF, in conflict with previous
results [28]. The promise of GABA-related markers
was further dampened after results of a randomized,
double-blind, placebo-controlled crossover, clinical
trial in 4 HD patients using Isoniazid (with pyridox-
ine), a treatment which increased GABA [29]. This
failed to produce significant improvement in clini-
cal measurements [30] but did produce side effects.
A later study analyzing the samples obtained from
this trial revealed that, in addition to GABA eleva-
tion, isoniazid treatment increased levels of aspartate,
asparagine, homocarnosine, ornithine, histidine, a-
aminobutyric acid, isoleucine, leucine and alanine
in CSF [31]. Manyam et al. concluded that the
therapy’s effect on amino acids in general likely con-
tributed to the undesired clinical response observed
as a result of the treatment. GABA has not been re-
studied since 1987 but, on the evidence to date, it
seems unlikely to be a clinically relevant marker of
disease [32].
Similarly to GABA, choline-related proteins
were measured in HD CSF because of loss of neu-
rons using acetylcholine and the caudate, affected
disproportionately in HD, having the highest acetyl-
cholinesterase (AChE) activity in the brain. After
having shown the broad effects of isoniazid, Manyam
et al. extended their study to include choline [33].
They measured levels of choline and AChE activity
in CSF samples from the 6 placebo-treated HD
patients, and 9 controls who did not take part in
the trial. Choline was significantly lower after age
adjustment in HD patients compared to controls, but
AChE showed no difference. There was no effect
on choline levels and AChE activity after treatment
with isoniazid.
Other amino acids were investigated using high
pressure ion-exchange chromatography in a study
involving 12 HD patients, 8 at-risk offspring and
16 non-choreic controls, each having morning CSF
collection after fasting – a study design ahead of
its time for minimizing potential confounders [34].
Out of the 27 measured, lower levels in HD patients
were seen in asparagine, isoleucine, leucine, pheny-
lalanine, histidine, arginine, alpha-aminoadipic acid
and homocarnosine compared to non-choreic con-
trols, with tyrosine the only to increase. At-risk
offspring were split into two groups with 5 stated
to be “neurophysiologically conspicuous offspring”
(based on eye movement disturbance in electronys-
tagmographic examinations) and displaying a similar
trend of amino acid imbalance in the CSF. This may
indicate early disturbance of metabolism in HD but
because of low sample number, lack of a genetic
test to identify gene carriers in the at-risk offspring,
and no replication of these results since the genetic
test was established, it remains unclear whether any
neurotransmitter amino acids could provide early
markers of disease onset.
The striatum receives dopaminergic input from
the substantia nigra. Neuronal loss in the striatum –
and therefore loss of postsynaptic striatal dopamine
receptors – during the course of HD creates an imbal-
ance due to a reduction in dopamine uptake (DA).
This disproportion was thought to potentially con-
tribute to chorea on the basis of an overactive effect
of dopamine on the striatum [35]. Dopamine (DA)
metabolites were therefore a source of early interest
as possible CSF markers.
Homovanillic acid (HVA) a CSF metabolite of
DA and indicator of dopaminergic activity, has been
measured in HD on several occasions, generating
contradictory findings. Where some have found no
difference in CSF HVA in HD [36, 37] others
reported a reduction [38] – neither case supporting the
original theory of overactive dopamine. DA metabo-
lites studied by Garrett and colleagues in HD CSF
included DA itself, 3,4-dihydroxyphenylacetic acid
(DOPAC), homovanillic acid (HVA), noradrenaline
(NA), 3-methoxy-4-hydroxyphenylglycol (MHPG),
and 5-hydroxyindoleacetic acid (5-HIAA). Increased
CSF levels of DA and DOPAC were taken to reflect
increased dopaminergic activity in HD yet levels of
HVA were not significantly different [39].
Garcı´a Ruiz and colleagues again measured CSF
levels of HVA, 5-HIAA, and tryptophan in 20 HD
patients against four control groups: 15 healthy con-
trols, 23 untreated PD patients, 38 patients with
dystonia and 61 patients with other neurological
disorders, using high-performance liquid chromatog-
raphy (HPLC) with electrochemical detection [40].
HVA was significantly lower in HD compared
to controls and other neurological patients adding
more evidence that HVA is not a reliable marker
of dopaminergic activity and the true role of the
dopaminergic pathway in HD is poorly understood.
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TRANSGLUTAMINASE ACTIVITY
Polyglutamine – the expanded amino acid
sequence that confers toxicity upon mHTT – has
been shown to be a good substrate for transglu-
taminases, enzymes that catalyze linkage reactions
between substances containing glutaminyl and lysyl
residues or polyamines. Polyglutamine expansion
in HD increases its effectiveness as a substrate for
transglutaminases in vitro. Transglutaminases have
been implicated in the aggregation of mHTT, and
cystamine (among other actions, an inhibitor of trans-
glutaminase) ameliorated symptoms in transgenic
HD mice, supporting the notion that transglutam-
inase activity may contribute to the toxic gain of
function of mHTT [41]. N-(-l-Glutamyl)-l-lysine
(GGEL) is one substance produced from a transg-
lutaminase reaction and therefore used as a marker
for transglutaminase activity. Jeitner et al. found sig-
nificantly higher levels of GGEL in CSF of 36 HD
patients compared to 27 controls (being treated for
various spinal injuries) using liquid chromatography
with electrochemical detection (LCEC) [42]. Build-
ing on the previous evidence from GGEL levels in
HD CSF, Jeitner and colleagues went on to inves-
tigate whether other glutamylpolyamines would also
reflect alterations of TGase activity in HD. They used
HPLC-EC to quantify GGEL,-glutamylspermidine,
-glutamylputrescine, and bis--glutamylputrescine
simultaneously in CSF [43]. These were all found
to be elevated in manifest HD compared to con-
trols. Cysteamine, a reduced form of cystamine, was
recently tested in a clinical trial in HD patients.
The results have only so far been released in unre-
viewed summary form; the drug did not meet its
primary endpoint and CSF was not collected so
pharmacodynamic data on the compound’s putative
transglutaminase inhibitor mechanism will not be
forthcoming [44].
KYNURENINE PATHWAY METABOLITES
The NMDA receptor agonist quinolinic acid (QA),
and the concept of excitotoxicity as a contributor to
neuropathology, became of huge interest in HD CSF
after it was discovered that direct intra-striatal admin-
istration is selectively toxic to medium spiny neurons
and produces deficits that mimic some aspects of HD.
Before the identification of the causative gene, QA-
lesioned rodents were the main experimental model
for HD.
QA is a downstream product of the kynurenine
pathway, by which the neurotransmitter amino acid
tryptophan is degraded in mammals [45]. As well
as its possible role in HD neuropathology, affirmed
by subsequent work in animal models and human
post-mortem samples [46, 47], the pathway and in
particular the enzyme kynurenine mono-oxygenase,
is a high-priority target for therapeutic development
[1]. Its study in CSF also serves to illustrate the his-
torical shortcomings in the field and the urgent need
for greater rigor.
From the observations in animal and human brains,
it was initially hypothesized that an increase would be
seen in QA in HD patient CSF but in one study using
a radioenzymatic assay, no significant difference was
observed [48]. This study included just 10 patients
and 7 controls and was most likely underpowered to
detect an effect, especially given its controls were
patients with schizophrenia and there was no stan-
dardization of dietary conditions (known to affect KP
metabolite levels) or the time of day when samples
were collected, and no information recorded about
medications or the processing of CSF samples.
In a second study three years later, a similar result
was found but this was a faithful replication inasmuch
as it suffered the same shortcomings as the original
work: Small subject numbers (9 patients and 9 ‘hospi-
tal patient’ controls), no standardization of sampling
or processing conditions and insufficient information
about possible confounds such as medication [49].
In a broad-ranging study in 1992, Heyes and col-
leagues set out to quantify several KP metabolites in
CSF from HD patients and a broad range of other neu-
rological and physical diseases. The total number of
subjects was large but the HD sample relatively small
and inconsistently reported (the number of patients
was reported as both 30 and 13). Using HPLC they
found CSF levels of the neuroprotective metabolite
kynurenic acid (KA) were lower in HD than in con-
trols, and a similar pattern in Alzheimer’s disease;
CSF QA was elevated in inflammatory disease but
not altered in neurodegenerative diseases [50]. The
decreased KA finding echoed an earlier report from
23 HD patients and 50 controls “undergoing myelog-
raphy or being evaluated for fever or headache” by
Beal and colleagues [51].
This cluster of publications on CSF kynurenine
pathway metabolites is edifying. There were – and
still are – strong reasons to suspect that relevant,
disease-related alterations in metabolites ought to be
detectable in CSF; but the only studies available to us
in 2016 were conducted using inconsistent methods
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over two decades ago – before we could even be cer-
tain that the patient volunteers had HD rather than a
phenocopy syndrome – and yielded mixed or negative
results we cannot interpret because they likely lacked
the power to test their hypotheses definitively.
OXIDATIVE STRESS
Oxidative damage has been associated with many
neurodegenerative diseases including HD [52] and
through early QA-lesioned animal models, their
study overlaps with the kynurenine pathway. Mark-
ers of oxidative stress have been investigated in HD
blood plasma and brain tissue of disease models but
few have been quantified in CSF. F2-isoprostanes
are a marker for lipid peroxidation. Using gas chro-
matography/negative ion chemical ionization mass
spectrometry (GC/NICIMS) these were found to be
significantly elevated in 20 HD patients but not in 7
patients with multiple system atrophy or in 23 con-
trols (who underwent CSF collection for diagnostic
purposes) [53]. Montine and colleagues had previ-
ously shown increased levels of F2-isoprostanes in
AD compared to controls [54] and used these results
for direct comparison to HD. It is important to note
that there was large overlap in disease groups and
controls, so the utility of F2-isoprostanes as mark-
ers of disease state appears low. Several clinical trials
of purportedly antioxidant compounds such as ethyl-
EPA [55] and coenzyme Q10 [56] have produced
negative clinical outcomes and the lack of suitable
pharmacodynamic CSF biomarkers precludes the
interpretation of possible subclinical effects.
INFLAMMATORY MARKERS
Overactivation of myeloid cells, including
microglia, and subtle abnormalities of the innate
immune system, are among the earliest biochemical
changes that have so far been detected in HD patients
[15, 57]. Most of this work has been carried out
in peripheral blood or ex vivo cells [58] but in
2007 Dalrymple and colleagues found that plasma
elevations of clusterin were mirrored in CSF from 20
patients and 10 controls in the first report from a CSF
collection with dedicated matched contemporaneous
healthy controls from the general population, rather
than from patients under investigation for other
conditions [12]. Their finding of elevated IL-6 and
IL-8 in blood plasma was reproduced in patient CSF
in 2008 by Bjo¨rkqvist, et al. [15].
More recently, YKL-40, a member of the glyco-
syl hydrolase family 18 and a marker of microglial
activation [59], was investigated as a CSF marker in
54 HD mutation carriers (27 manifest and 27 pre-
manifest) after reported elevation in other diseases
associated with neuroinflammation [60]. YKL-40
was noted to increase with age in healthy controls but,
after age-correction only a trend of elevated YKL-40
was seen in manifest HD that did not reach statistical
significance. Novel therapeutic approaches include
compounds aimed at modulating microglial activ-
ity (e.g. the current Legato-HD trial of laquinimod
[11]) so YKL-40 and other microglial and inflam-
matory markers remain of interest. It may be that an
emphasis on standardization of CSF collection and
processing methods, to eliminate variation from time
of day, medication or diet, can reveal these substances
to be useful markers reflecting relevant and tractable
disease-related changes in HD.
Similar to other neurodegenerative diseases, there
is an increase in clusterin levels as well as cytokines
IL-6 and IL-8 reported in HD [57]. A small sample
proteomic study detected significantly higher levels
of prothrombin and haptoglobin which both are pro-
teins associated with inflammatory response [61].
Like clusterin, IL-6 and IL-8, upregulation of hap-
toglobin has been seen in other diseases including
AD and traumatic brain injury [62, 63]. Prothrom-
bin correlated with disease severity and has yet to be
tested in other diseases. Further investigation will be
needed to ascertain its effectiveness as a CSF marker
for disease progression specific to HD.
NEUROENDOCRINE MARKERS
Hypothalamic neuroendocrine abnormalities have
been suggested to contribute to many symptoms
seen in HD such as weight loss, depression and
disruption of sleep [64], supported by evidence of
hypothalamic cell loss. Neuroendocrine markers have
been targets for several CSF studies in HD. Corti-
cotropin releasing factor (CRF) and 5-HIAA were
investigated in HD after higher and lower levels,
respectively, were observed in the CSF of patients
suffering from major depression [65, 66]. CRF and
5-HIAA were measured in 56 early stage HD patients
(drug-free) using a radioimmunoassay (for CRF)
and HPLC (for 5-HIAA) [67]. Aliquots were taken
from 21 subjects with no known neurological dis-
ease and undergoing spinal anesthesia for control
comparison of CRF, while a control group of 4
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individuals was used to compare levels of 5-HIAA.
Mean CRF was higher in HD patients (with or with-
out depression) than controls, and correlated with
severity of depression whereas 5-HIAA showed no
significant difference. Again, low sample numbers
are limiting and no demographic information was pre-
sented for the control group. Although a biochemical
underpinning for depressive symptoms in HD seems
plausible, little can be concluded with confidence
here.
Ghrelin, the ‘hunger’ hormone which also regu-
lates the reward mechanism in dopamine neurons
and effects sleep and depression, was quantified in
plasma and CSF (15 HD patients and 20 healthy
controls) alongside leptin, a hormone associated
with satiety [68]. Ghrelin was increased and lep-
tin decreased in plasma of the HD patients but
neither was altered in CSF. Orexin A (hypocretin)
levels were investigated by Bjo¨rkqvist and col-
leagues in 37 HD patients and 30 controls, but no
significant differences were found and this was repli-
cated in two separate studies [69–71]. Cocaine and
amphetamine regulated transcript (CART), a neu-
ropeptide associated in increased anxiety and lower
food intake was significantly higher in HD CSF
(n = 39) compared to control CSF (n = 29), after quan-
tification using a radioimmunoassay [72]. Bjo¨rkqvist
and colleagues investigated the relationship between
anxiety symptoms and levels of CSF CART but
found no significant correlation. Evidence for ele-
vated CART in HD CSF was replicated by Gabery
et al. [73].
PROTEIN MARKERS OF NEURONAL
DEATH
Proteins released by dying neurons that can be
quantified in CSF have been studied much more
comprehensively in other neurological diseases than
in HD. Tau protein (a component of microtubules)
and the light subunit of neurofilament triple protein
(NFL, a component of the neuronal cytoskeleton)
are reasonably well-established as markers of neu-
ronal death that appear to be widely applicable
across neurodegenerative diseases [74]. Tau in par-
ticular is already in clinical use in the diagnostic
process of Alzheimer’s disease alongside with lev-
els of beta-amyloid species. Tau and NFL have both
been examined in small sample sets in HD. NFL
levels were higher in the CSF of 35 HD patients
compared to 35 matched controls, and correlated
with UHDRS Total Functional Capacity [75], a clin-
ical measure of disease progression. The same group
measured CSF levels of tau and found a significant
elevation in HD though, due to overlap, tau could
not provide categorical distinction between groups
and showed no correlations with clinical measures
[76]. As with many initial findings, these results
have yet to be replicated and the effect of inter-
subject variability in sampling conditions remains
to be seen.
A further complication in the investigation of low-
abundance proteins in CSF is the effect of different
materials used in sample handling. Polystyrene and
polyethylene tubes have been shown to artefactually
diminish CSF levels of amyloid beta compared with
polypropylene tubes, through adsorption of the pro-
tein to the plastic surface [77]. Similar effects may
well be seen with any other protein; most have not
been investigated for such technical effects. Such
observations call for absolutely strict standardiza-
tion of all equipment within and between studies.
In our experience this requires great effort and close
attention, since we are aware of at least two cases
where plasticware described by the manufacturer as
polypropylene has later emerged as being made from
another plastic. Other granular technical considera-
tions such as aliquot size can have a significant effect
on the measured levels of proteins [78]. Careful plan-
ning and due diligence around all aspects of CSF
studies are paramount.
PROTEOMIC APPROACHES
In contrast to hypothesis-driven approaches, pro-
teomic discovery has the potential to identify
novel biomarker candidates and pathogenic path-
ways through the analysis of many proteins from the
same sample. In HD CSF, proteomic work has so
far been limited by small sample sizes and lack of
necessary analytic technology. Fang and colleagues
integrated 5 sets of proteomic profiles, obtained
by different laboratories, from a single HD sam-
ple set. They incorporated gene expression profiling
data from a study by Ge et al. [79] to identify
the most probable origin of the detected proteins.
As expected, they showed that brain-specific pro-
teins were more likely to be found in CSF than in
plasma. Inevitably they identified many proteins that
were altered in HD CSF, but the majority of these
disease-associated changes were in proteins which
were said to be liver-specific. There was a rather sur-
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prising tendency for brain-derived proteins to decline
in HD CSF, with the exception of neuroinflammatory
markers [80]. These findings highlight the inconsis-
tencies between proteomic techniques and the nature
of such studies as hypothesis-generating engines for
future targeted work in properly powered sample
sets. This replication work has yet to be carried
out in HD.
A small sample proteomic study of 9 HD patients
detected significantly higher levels of the immune-
associated proteins prothrombin and haptoglobin (see
Inflammatory Markers, above) as well as Apolipopro-
tein A-IV (ApoA). ApoA is a glycoprotein associated
with inhibition of food intake and regulation of body
weight. All three were higher in HD patients com-
pared to matched controls [61] but these changes
were not independently replicated using a more quan-
titative assay – though Fang and colleagues had also
found robust elevations of ApoA in HD CSF in their
previous proteomic work [80].
Another proteomic study used surface-enhanced
laser desorption/ionization time-of-flight (SELDI-
TOF) mass spectrometry to analyze the proteomic
profile of CSF from 39 preHD gene carriers, 55
manifest HD and 27 HD gene negative controls.
10 out of the 85 peaks detected showed signifi-
cant difference between manifest HD and controls.
After age-adjustment and Bonferroni correction, only
ubiquitin remained significantly higher in mani-
fest HD patients, with a trend in preHD compared
to controls. The correlation between ubiquitin and
CAG-age product (CAP) and other clinical measures
was statistically significant [81]. Ubiquitin is added
post-transcriptionally to flag proteins for degradation
by the ubitiquitin-proteaseome system (UPS), and its
elevation in CSF may reflect the gradual accumula-
tion of unwanted proteins, perhaps including mHTT,
in cells of the CNS. Failure of the UPS to cope with
the buildup of abnormal proteins is suggested to be
involved in the pathogenesis of HD and other neu-
rodegenerative diseases [82]. This finding warrants
further investigation and its longitudinal predictive
value needs to be determined in a suitable patient
cohort.
MUTANT HUNTINGTIN
Understanding the function of the huntingtin pro-
tein and its mutant counterpart has been a major
focus of HD research since the gene was discovered
in 1993. With many approaches aimed at reducing
the expression of mHTT, its quantification in CSF
has been highly desirable but proved extremely chal-
lenging. mHTT is a large, aggregation-prone protein
expressed mostly intracellularly, and since HD gen-
erally progresses slowly, mHTT would be expected
to be released very gradually into the CSF from
dying neurons. Consequently its CSF concentration
is certainly extremely low and several generations of
improvement in antibodies and mHTT-quantifying
assays failed to yield a method sensitive enough to
quantify it [19].
Successful quantification of soluble CSF mutant
huntingtin was only achieved in early 2015 [83]. We
used a single molecule counting (SMC) immunoas-
say, and a combination of HTT N-terminal-detecting
2B7 antibody and polyglutamine-binding MW1 anti-
body, to quantify mHTT for the first time in CSF at
femtomolar sensitivity (Fig. 2). mHTT was signifi-
cantly higher in manifest HD and preHD compared
to controls with a roughly threefold difference seen
between preHD and manifest. mHTT also corre-
lated with clinical phenotype as measured by motor
and cognitive scores. Crucially, these associations
remained statistically significant after adjustment for
disease burden score (a product of age and CAG
repeat length), indicating that CSF mHTT level has
independent power to predict clinical phenotype in
HD – the first molecular measure reported to show
this ability. Moreover, mHTT level was seen to cor-
relate significantly with CSF concentrations of NFL
and Tau, suggesting a neuronal origin for the mHTT
detected. These findings were shown in two indepen-
dent cohorts of 12 participants in London and 40 in
Vancouver. Work is now underway to validate this
assay according to the Food and Drug Administra-
tion (FDA) and European Medicines Agency (EMA)
guidelines for biomarker validation for clinical trial
use. Assays for total huntingtin level are also under
development.
Shortly afterwards, Southwell and colleagues
reported mHTT quantification in CSF with immuno-
precipitation and flow cytometry (IP-FCM) using
a combination of MW1 and HDB4E10 antibodies,
the latter recognizing a C-terminal binding site [84].
In a single cohort, overlapping with the Vancouver
dataset from our work, they confirmed the presence
of mHTT in mutation carriers but not controls and
a tendency to rise with onset and clinical manifes-
tations. They went on to show that the assay was
capable of detecting mHTT in CSF from Hu97/18
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Fig. 2. First successful quantification of mHTT in CSF using the Singulex SMC immunoassay. mHTT was significantly higher in premanifest
than controls and in manifest HD than premanifest in two cohorts from (A) London cohort and (B) Vancouver. mHTT correlated with (C)
disease burden score and (D) Unified Huntington’s Disease Rating Scale motor score. Adapted from Wild et al. [83] with the author’s and
publisher’s permission.
mice expressing human mHTT, and that the signal in
CSF was correlated significantly with brain mHTT
level after intracerebroventricular administration of
an HTT-lowering antisense oligonucleotide. These
findings (Fig. 3) confirm a likely neuronal origin for
mHTT detected in CSF and affirm its promise as a
highly pathogenically relevant biomarker for HTT-
lowering trials.
Both these assays and their successors under devel-
opment are likely to be valuable in the investigation of
HTT in CSF in humans and model animals. While the
SMC immunoassay appears highly robust and repro-
ducible, and gives a more quantitative indication of
concentration, perhaps making it the more likely can-
didate for clinical trial use, the IP-FCM assay uses
more widely available technology and may there-
fore find a more widespread role in the preclinical
setting.
All forms of mutant huntingtin are not alike, and
a means of quantifying the most pathogenic forms in
CSF would be valuable. Tan and colleagues devel-
oped a cell-based aggregation assay to quantify the
proportion of cells with aggregates, and amount of
aggregates in lysate, and demonstrated that seeding
of aggregation could be triggered by synthetic polyg-
lutamine oligomers and by CSF from transgenic rats
and human HD patients [85]. The study provides the
first evidence that CSF could be used to study not
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Fig. 3. CSF mHTT positively correlates with brain levels after treatment of HTT-lowering anti-sense oligonucleotide. The IP-FCM mHTT
assay confirmed (A) mHTT can distinguish between controls and gene carriers; (B) mHTT levels in brain lysate and CSF strongly correlate
after HTT-lowering treatment; and reduction in mHTT levels increases with ASO dosage in (C) brain and (D) CSF. Adapted from Southwell
et al. [83] with the author’s and publisher’s permission.
only the quantity of mHTT but its pathogenic proper-
ties, offering potential as a diagnostic and prognostic
marker.
CONCLUSION
It is ever more likely that robust, useful CSF
biomarkers of HD will be developed. The current
challenge is not a numerical shortage of hypotheses
or of small studies proposing potential CSF biomark-
ers for HD. The investigators in the early studies
established the field using the methods and standards
of the day, and it would be unfair to judge them
by standards that have changed dramatically in the
intervening decades. We now have at our disposal
advanced methodologies for sensitively, accurately
and reproducibly quantifying metabolites in bioflu-
ids. Moreover we are now definitively in a new era
where targeted HD therapeutics are entering clinical
trials, giving more pressing reasons than ever to wish
to know what HD-related changes can be found, or
what drug-induced changes can be detected.
Experience from other neurodegenerative diseases
suggests that the greatest prima facie utility for neu-
ronal proteins in CSF is as natural history biomarkers.
A small cadre of such candidates can be proposed
based on findings in HD to date: Tau and NFL to mea-
sure neuronal death and mHTT as a ‘smoking gun’ –
the disease agent itself, released from the neurons it
is killing. Even these require urgent replication and
longitudinal study to examine their prognostic powers
and response to therapeutic intervention.
Other classes of biomarker may be able to shed
light on specific aspects of HD natural history or
progression, and in carefully chosen contexts may
serve as targeted pharmacodynamic markers for clin-
ical trials of specific therapeutics. But each of these
dozens of proposed markers and its assay requires
full replication and validation according to stringent
criteria if they are to meet their potential to advance
therapeutics.
The greatest challenge is to replicate previous
promising findings in large adequately powered
cohorts using the latest assay techniques, and the
unglamorous but crucial work of standardizing meth-
ods across sites and between studies. CSF collection
efforts need to move from ad hoc to concerted, with
optimized protocols and equipment and with controls
recruited contemporaneously from an age-matched,
genuinely healthy population. Clinical phenotyp-
ing needs to be comprehensive and standardized
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based on the best available evidence. With these
aims in mind, we have embarked on HDClarity
(http://hdclarity.net), a major multi-site study of CSF
in HD, which aims to recruit 600 participants at up
to 30 sites globally using optimized techniques with
rigorous quality control and assurance. These sam-
ples and data will be subject to multiple analyses to
identify head-to-head those biomarkers with the most
power to detect disease-related changes in HD or to
act as pharmacodynamic tools to facilitate the rapid
testing of a new generation of promising therapeutic
candidates.
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